Rabi Hanna: First-in-Human CRISPR/Cas12a Therapy in Sickle Cell Disease
oncodaily - Rabi Hanna, Pediatric Blood and Marrow Transplant Program Director, and Chairman at the Department of Pediatric Hematology-Oncology and BMT at Cleveland Clinic, shared a post on LinkedIn: “I am excited […]
AI Summary: A first‑in‑human CRISPR/Cas12a therapy for sickle cell disease has treated initial patients, building on preclinical gene‑editing successes that reversed severe disease in models. The advance underscores rapid translation from lab to clinic and renews hope for durable cures—while reminding everyone that the safety and long‑term durability questions remain firmly on the table.
Uveal Melanoma: ESMO–EURACAN Clinical Practice Guideline
esmo - This ESMO–EURACAN CPG provides key recommendations for the diagnosis, staging, treatment and follow-up for uveal melanoma. It includes percutaneous hepatic perfusion and tebentafusp as treatment options for metastatic disease, reflecting emerging evidence…
AI Summary: ESMO–EURACAN released a comprehensive clinical practice guideline for uveal melanoma covering diagnosis, staging, surveillance and systemic management. The guidance clarifies best practices for multidisciplinary care, risk stratification and therapeutic sequencing, aiming to standardize treatment and follow‑up for a rare but high‑risk ocular tumour.
CHS sells 180-bed hospital for $459M: 6 things to know
Alan Condon / beckershospitalreview - Franklin, Tenn.-based Community Health Systems on April 1 sold Crestwood Medical Center — a 180-bed hospital in Huntsville, Ala. — to Huntsville Hospital Health System for $459 million. Six things to know: 1. The deal includes all of the assets tied to th…
AI Summary: Community Health Systems has finalized the sale of a 180‑bed Alabama hospital for $459 million, concluding a transaction that reshuffles local care ownership and may prompt operational changes. The closing marks a notable consolidation step in regional hospital markets and raises questions about continuity and access as the new owner assumes control.
Bowelbabe Fund celebrates raising £20m by announcing the Bowelbabe Vaccine
Sophie Wedekind / cancerresearchuk - The Bowelbabe Fund has raised more that £20 million and has announced the next wave of funded projects, including the Bowelbabe Vaccine.The post Bowelbabe Fund celebrates raising £20m by announcing the Bowelbabe Vaccine appeared first on Cancer Research U…
AI Summary: The Bowelbabe Fund celebrated a £20 million fundraising milestone and unveiled plans for a Bowelbabe Vaccine initiative, drawing high‑profile support. Organizers framed the cash infusion as a catalyst for prevention and research efforts, while public endorsements highlighted momentum — and the fundraising thermometer that finally stopped making them blush.
Targeted, High-dose Radiation May Improve Treatment for ‘Supermassive’ Bile Duct Tumors
Kathleen Medora / aacr - Patients with very large intrahepatic cholangiocarcinoma experienced improved outcomes when targeted, high-dose radiation was added to chemotherapy PHILADELPHIA – Patients with supermassive intrahepatic cholangiocarcinoma (ICC) benefited from ablative rad…
AI Summary: New clinical reports indicate that targeted high‑dose radiation can improve outcomes for very large “supermassive” bile duct tumors, offering better local control and symptom relief than conventional approaches. Early data suggest this intensity‑modulated strategy may expand options for otherwise difficult‑to‑treat cases, though longer follow‑up is needed to confirm survival benefits.
FDA identifies eight deaths tied to Amgen's Tavneos
Max Bayer / endpoints - The FDA on Tuesday flagged more than 70 cases of severe liver injury and eight deaths associated with Amgen’s autoimmune treatment Tavneos, but the company said it previously notified the agency about the risk of ...
AI Summary: The FDA has tied eight patient deaths to Amgen’s drug Tavneos, prompting heightened regulatory review and industry concern. Reports outline safety signals and agency actions as clinicians and manufacturers reassess risk‑benefit profiles, while regulators weigh labeling, monitoring or other interventions to protect patients.
Biogen to acquire Apellis for $5.6B
Elizabeth Cairns / endpoints - Biogen has made a $5.6 billion deal to acquire Apellis Pharmaceuticals, the companies announced Tuesday. The deal will allow Biogen to get hold of the kidney disease drug Empaveli and the eye disease therapy Syfovre ...
AI Summary: Biogen agreed to acquire Apellis Pharmaceuticals for $5.6 billion, a deal pitched as a strategic move to broaden Biogen’s pipeline and bolster its biopharma foothold. Analysts and company spokespeople framed the purchase as value‑accretive, even as skeptics question integration risks and the price tag in a cautious market.
Memorial Hermann goes out of network with BCBS Texas
Elizabeth Casolo / beckershospitalreview - Houston-based Memorial Hermann Health System’s contract with BCBS Texas expired April 1, rendering the health system out of network. Commercial and ACA exchange (both individual and family) plan members lost access at the end of March. Memorial Hermann ha…
AI Summary: Memorial Hermann and Blue Cross Blue Shield of Texas failed to agree on a new contract, resulting in the health system going out of network for affected plan members. Patients face potential higher costs and care disruptions while negotiators jockey publicly; both sides warn of financial stakes and urge members to stay informed.
White House floats 12.5% budget cut for HHS in FY2027, reiterates reorganization plan
fiercehealthcare - The requested budget cut is about half of what the administration asked, and was denied, last year. However, plans for reorganizing agencies under an Administration for a Healthy America persist, as do calls to eliminate various programs and centers the W…
AI Summary: The administration has floated a plan to cut HHS funding by roughly 12–12.5% in FY2027 while pursuing agency reorganization. The proposal targets discretionary programs including research funding, prompting scientific groups to urge Congress to reject the NIH reductions and warn of downstream impacts on biomedical research and patient care.
- Researchers, cancer groups warn NIH cuts will harm patients (6)
- White House pushes deep HHS cuts, agency reorganization (4)
- All Other Stories
Researchers, cancer groups warn NIH cuts will harm patients
White House pushes deep HHS cuts, agency reorganization
All Other Stories
Why 131 Hospitals Are Suing HHS Over Alleged Underpayment
Katie Adams / medcitynews - A group of 131 hospitals has sued HHS over a CMS policy they say improperly reduces Medicare disproportionate share hospital (DSH) payments. The lawsuit is the latest in a decade-long legal battle over how the agency counts patient days and calculates pay…
AI Summary: One hundred thirty‑one hospitals have filed suit challenging HHS’s 2023 Disproportionate Share Hospital calculation, arguing the agency’s formula undercounts uncompensated care and systematically underpays safety‑net providers. The plaintiffs seek to overturn the rule and recover alleged shortfalls, warning that ongoing underpayment threatens hospital finances and patient access.
CMS finalizes Medicare Advantage star ratings overhaul, sending billions of dollars more to insurers
Rebecca Pifer Parduhn / healthcaredive - Regulators cut almost a dozen metrics that factor into the quality ratings and reverted back to an older and more generous bonus system. MA plans will get more than $18 billion in additional payments over the next decade as a result.
AI Summary: The Centers for Medicare & Medicaid Services locked in a sweeping overhaul of Medicare Advantage star ratings that will shift billions of dollars in payments and alter plan incentives. The ruling adjusts rating calculations and enrollment provisions, prompting industry and provider concerns about downstream effects on access, plan behavior, and provider-network stability.
AI scribe adoption linked to modest reductions in EHR, documentation time: study
Emily Olsen / healthcaredive - Clinicians’ use of an AI scribe was associated with 13 fewer minutes each day inside electronic health records and 16 fewer minutes on documenting patient care, according to the research published in JAMA.
AI Summary: A multi‑site study found adoption of AI medical scribes yields small but consistent reductions in electronic health record documentation and clinician charting time. Hospitals reported time savings and workflow adjustments, but gains were modest — enough to raise eyebrows, not replace human scribes or magic.
- Companies push AI beyond notes — coding, decision support, geriatric assessments (3)
- Frontline adoption: health systems pilot ambient AI, Epic integration underway (5)
- Multisite study finds AI scribes slightly cut clinicians' EHR time (3)
- All Other Stories
Companies push AI beyond notes — coding, decision support, geriatric assessments
Frontline adoption: health systems pilot ambient AI, Epic integration underway
Multisite study finds AI scribes slightly cut clinicians' EHR time
All Other Stories
Group sues CMS for details on Medicare AI prior authorization pilot
Andrew Cass / beckershospitalreview - Digital rights advocacy organization the Electronic Frontier Foundation has filed a Freedom of Information Act lawsuit against CMS seeking information on how the AI algorithms work in its traditional Medicare prior authorization pilot. CMS’ Wasteful and I…
AI Summary: A coalition of tech and privacy groups has sued CMS seeking detailed records about a Medicare pilot that uses AI to automate prior authorization decisions. Plaintiffs argue the agency failed to provide transparency on algorithms, data inputs and patient safeguards, demanding documents to assess legal, safety and fairness risks before the program expands.
WHOOP Secures $575M, Reaches $10B Valuation
Marissa Plescia / medcitynews - WHOOP’S Series G round was led by Collaborative Fund and includes participation from 2PointZero Group, Qatar Investment Authority, Cristiano Ronaldo and LeBron James.The post WHOOP Secures $575M, Reaches $10B Valuation appeared first on MedCity News.
AI Summary: Wearable fitness company Whoop closed a $575 million funding round that values the business at roughly $10 billion, attracting strategic partners including Abbott and health systems like Mayo Clinic. The cash infusion underwrites an aggressive hiring spree and product expansion as Whoop doubles down on clinical collaborations and scaling its sensor and analytics platform.
Eli Lilly’s Neuro Prospects Expand to Sleep Science With $6.3B Centessa Acquisition
Frank Vinluan / medcitynews - Centessa Pharmaceuticals’ cleminorexton is part of the orexin agonist drug class, which could introduce a new approach to the treatment of narcolepsy and other sleep disorders. Acquiring Centessa brings Eli Lilly into a group of clinical-stage orexin agon…
AI Summary: Eli Lilly announced a $6.3 billion acquisition of Centessa to secure a promising narcolepsy/sleep-disorder candidate and expand its neuroscience portfolio. The deal fast-tracks Lilly into sleep science, buying late-stage assets rather than relying on in-house miracles — a tidy shortcut to diversifying its neurotherapeutics pipeline.
CMS: This year's open enrollment brought fewer signups, higher premiums
fiercehealthcare - The administration's official numbers on the 2026 Open Enrollment Period outlined drops in new customers and automatic re-enrollment, the latter of which CMS said stemmed from its crackdown on improper enrollments. Average monthly premiums also increased …
AI Summary: CMS data show this year's ACA open enrollment produced fewer new signups while benchmark premiums climbed, nudging many consumers into higher‑deductible plans. Enrollment sits near 23.1 million for 2026, but the mix of coverage is tilting toward cost‑sharing over comprehensiveness, raising concerns about affordability and surprising out‑of‑pocket shocks for vulnerable families.
What you should know about the new COVID-19 'Cicada' variant
medicalxpress - A new COVID-19 variant that some have dubbed the "Cicada" variant is quietly spreading across the globe, carrying an unusually high number of mutations that could help it slip past existing immunity, public health experts say. The strain of SARS-CoV-2, ca…
AI Summary: A newly identified SARS‑CoV‑2 lineage nicknamed "Cicada" is showing signs of increased spread, prompting CDC tracking and expert concern. Public health officials advise heightened surveillance, updated testing and genomic sequencing to determine transmissibility, immune escape and clinical impact, while researchers rush to characterize the variant’s risks and inform any needed response.
The new cholesterol guideline: What to know
medicalxpress - For the first time since 2018, a clinical guideline from the American College of Cardiology and the American Heart Association for screening and managing blood cholesterol levels has been updated and jointly published in the Journal of the American Colleg…
AI Summary: Updated cholesterol guidance proposes shifts in testing strategy and risk assessment that may change timing and targets for lipid screening. Clinicians and patients should expect revised thresholds and more personalized testing intervals as the guideline aims to better align prevention with individual cardiovascular risk—so yes, your testing schedule might get a makeover.
- Diet and Upstream Prevention — Community diets and upstream prevention fight heart disease (3)
- OTHER — Triglyceride drug failed to reduce arterial plaque (1)
- Screening and Risk Tools — Earlier screening, personalized risk: guidelines meet AI (3)
- Treatment Advances and Intensive LDL — Aggressive LDL and new drugs reshape prevention strategies (3)
- All Other Stories
Diet and Upstream Prevention — Community diets and upstream prevention fight heart disease
OTHER — Triglyceride drug failed to reduce arterial plaque
Screening and Risk Tools — Earlier screening, personalized risk: guidelines meet AI
Treatment Advances and Intensive LDL — Aggressive LDL and new drugs reshape prevention strategies
All Other Stories
Teens are driving the demand for online abortion pills via telehealth
medicalxpress - Teens in the U.S. are obtaining medication abortion pills through telehealth, and young people aged 18 to 24 are ordering medication abortion at much higher rates than older adults.
AI Summary: Telehealth provision of medication abortion has surged, reducing travel for many and prompting a noticeable uptick in online requests from teenagers. Reports show virtual care is reshaping access patterns and forcing healthcare systems and regulators to confront new realities around remote prescribing, confidentiality, and youth access to reproductive services.
NorthStar Trial Analysis at ELCC 2026: Local Consolidative Therapy in EGFR-Mutant NSCLC
oncodaily - The management of metastatic EGFR-mutant non-small cell lung cancer (NSCLC) has been transformed by the introduction of third-generation EGFR tyrosine kinase inhibitors, particularly osimertinib. While systemic therapy achieves meaningful disease […]
AI Summary: ELCC 2026 brought together clinicians and investigators to present pivotal lung‑cancer studies, including localized consolidative therapy, SBRT sequencing with immunotherapy, and trials addressing under‑represented KRAS and EGFR populations. The conference highlighted survival and tumor‑control signals, networked international collaborators, and emphasized real‑world applicability — proving once again that conferences are where hope meets peer review.
- At ELCC: late‑breaking trials reshaping clinical practice (6)
- OTHER: misc lung oncology studies, regulatory and surgical updates (8)
- Precision push: molecular testing, KRAS degraders, ADC collaborations advancing care (6)
- Voices from ELCC: clinicians share breakthroughs and practical takeaways (17)
- All Other Stories